Sana Biotechnology plans EASD 2026 symposium presentation on hypoimmune islet transplant without immunosuppression

Sana Biotechnology, Inc.

Sana Biotechnology, Inc.

SANA

0.00
  • Sana set an October 2, 2026 EASD symposium slot to present clinical data on UP421 hypoimmune allogeneic islet transplantation without immunosuppression.
  • Presentation will outline a path toward durable immune-evasive islet grafts, supporting a strategy to broaden cell therapy use in type 1 diabetes.
  • Focus remains on engineered-cell medicines, with platform work aimed at replacing damaged cells and scaling availability to more patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sana Biotechnology Inc. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.